Multiple Sclerosis

NEUROLOGY 3m 44s What Is Multiple Sclerosis? JN Learning

NEUROLOGY 30m 15s 0.5 Credit CME Stanford Medcast Episode: Hot Topics Mini-Series - Stem Cell Therapy in Multiple Sclerosis Stanford Medicine

NEUROLOGY 30m 36s 0.5 Credit CME Stanford Medcast Episode: Hot Topics Mini-Series - Gut Microbiome in Multiple Sclerosis Stanford Medicine

NEUROLOGY 38m 40s 0.75 Credit CME Multiple Sclerosis Lecture Series: Diagnosis Stanford Medicine

NEUROLOGY 34m 57s 0.5 Credit CME Multiple Sclerosis Lecture Series: MS 101 Stanford Medicine

NEUROLOGY 31m 51s 0.5 Credit CME Stanford Medcast: Hot Topics Mini-Series – The Role of Epstein-Barr Virus in Multiple Sclerosis Stanford Medicine

VACCINATION 1 Credit CME Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab JAMA Neurology

VACCINATION 1 Credit CME Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination JAMA Neurology

NEUROLOGY 1 Credit CME Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden JAMA Network Open

DEMYELINATING DISORDERS 1 Credit CME Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis JAMA Neurology

VACCINATION 1 Credit CME Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies JAMA Neurology

ETHICS 1 Credit CME A Womanist Approach to Caring for Patients With Empirically Unverifiable Symptoms AMA Journal of Ethics

DEMYELINATING DISORDERS 1 Credit CME Association of a Marker of N -Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration JAMA Neurology

CORONAVIRUS (COVID-19) 0.5 Credit CME Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis JAMA Neurology

NEUROLOGY 1 Credit CME Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial JAMA Neurology

DEMYELINATING DISORDERS 1 Credit CME Diagnosis and Treatment of Multiple Sclerosis: A Review JAMA

NEUROLOGY 15m 27s 0.25 Credit CME Diagnosis and Treatment of Multiple Sclerosis—A Review JAMA

DEMYELINATING DISORDERS 1 Credit CME Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial JAMA Neurology

NEUROLOGY 28m 38s Optic Neuritis Incidence and Prevalence and Association With Systemic and Neurologic Disease JAMA Neurology